Analyze the information and social media posts to determine if the closing price of $bmy will ascend or descend at 2017-09-20. Please respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-09-06,0.2,0.7,-0.2,0.1,0.1,0.0,-1.2,-2.4,-2.9,-3.6,-4.2
2017-09-07,-3.7,1.0,-3.7,5.0,5.0,-3.6,-5.1,-6.5,-7.1,-7.7,-8.4
2017-09-08,0.2,0.9,-0.6,-0.4,-0.3,-2.6,-4.1,-5.5,-6.3,-6.9,-7.6
2017-09-11,-0.2,0.7,-0.9,0.2,0.2,-1.8,-3.5,-5.0,-5.9,-6.6,-7.3
2017-09-12,-0.9,0.1,-1.0,0.5,0.5,-1.3,-3.3,-4.8,-6.0,-6.7,-7.5
2017-09-13,0.6,1.0,-0.4,-0.9,-0.9,0.4,-1.9,-3.4,-4.8,-5.5,-6.3
2017-09-14,-0.5,0.7,-0.6,0.3,0.3,0.0,-1.7,-3.2,-4.7,-5.5,-6.2
2017-09-15,0.7,1.4,-0.3,-0.3,-0.3,0.3,-1.0,-2.5,-3.9,-4.8,-5.5
2017-09-18,-0.3,0.8,-0.7,0.4,0.4,-0.0,-0.9,-2.3,-3.7,-4.7,-5.5
2017-09-19,-0.4,0.3,-0.5,0.4,0.4,-0.4,-0.8,-2.2,-3.6,-4.7,-5.5

2017-09-06: rt AT_USER $bmy says opdivo multiple myeloma trials are on hold. no surprise given keytruda hold and subsequent fda news. |rt AT_USER following recent $mrk pembro news fda has placed partial clinical 
2017-09-07: rt AT_USER vantage snippet - keytruda¡¯s multiple myeloma fallout has roche in the firing line $mrk $bmy $azn $rhhby |rt AT_USER ipi/nivo beats sunitinib in 1l #kidneycancer by os. $bmy reports on pha
2017-09-08: bristol-myers squibb company $bmy svp joseph c. caldarella sells 9,340 shares |price moves vs expected moves $arry $abbv $mdt $agn $vrx $azn $biib $pfe $teva $bmy $gild $celg¡­ |update: $bmy also rele
2017-09-09: great slide by bmo expected sequence of events for key io trials in 1l-nsclc in 2h17, and our thoughts on implicati¡­ |rt AT_USER #crispr #cas9 offers grt hope for #glaucoma #opthalmology #ai $msft $g
2017-09-10: rt AT_USER presentation of day $bmy lag3 |$bmy heated as it hits the gap, hoping it rests and lest ma's catch up here |$bmy opdivo (nivolumab) demonstrates superior recurrence-free survival versus yer
2017-09-11: this week's most significant #insider trades: september 4-8, 2017 $bby $bmy $dps $f $hal $ph $psec $tjx¡­ |rt AT_USER mon-wed: morgan stanley 150 healthcare webcasts $abbv $agn $alxn $amgn $biib $blue
2017-09-12: s&amp;p100 #stocks performance $gd $amgn $msft $nee $rtn $bmy $celg $cat $fdx $jnj $pcln $mdt $dis $agn $intc  more@ |bristol-myers squibb company $bmy given average rating of ¡°hold¡± by analysts |th
2017-09-13: rt AT_USER event ¨c the next showdown in first-line lung cancer  $rhhby $bmy $mrk $azn|rt AT_USER just announced: leading cancer researcher karen vousden will join $bmy board of directors in january |
2017-09-14: seeking an edge in a fiercely fought field, $bmy pays $halo $105m to access i-o delivery tech #pharma |#bristolmyerssquibb bms inks $105m deal to access halozyme drug delivery tech. read more:  $bmy|#
2017-09-15: $halo ceo helen torley's relationship w/ $bmy didn't begin this week: |rt AT_USER willful manipulation, laziness, incompetence? $bmy escudier esmo cm-214 data dustup. must read story via AT_USER htt¡­
2017-09-16: rt AT_USER i'm counting days till first mention of $bmy's decision to study cancer immunotherapy subcutaneously via $halo enhanze by¡­|$bmy has a great technical rating! check out it's strong technica
2017-09-17: #bristolmyerssquibb halozyme leaps on news of multimillion dollar deals with bristolmyers an... read more:  $bmy|#bristolmyerssquibb this small cap biotech soars on deal with bristol-myers squibb. rea
2017-09-18: $bmy $mrk #stocks |rt AT_USER $bmy gorgeous coiled setup, size buyers of nov 65 calls today. |$bmy "they" are thinking about it. |rt AT_USER $bmy gorgeous coiled setup, size buyers of nov 65 calls tod
2017-09-19: evening most tweeted big caps, check out gambiste top 10: $jpm $ko $nvs $bmy $wbk $sny $msft $unh $pep $hd |$bmy is in three inside up winning 66.67% in the past. |rt AT_USER i called $bmy $halo 21 mo
Answer:
Analyze the information and social media posts to determine if the closing price of $bmy will ascend or descend at 2017-09-20. Please respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-09-06,0.2,0.7,-0.2,0.1,0.1,0.0,-1.2,-2.4,-2.9,-3.6,-4.2
2017-09-07,-3.7,1.0,-3.7,5.0,5.0,-3.6,-5.1,-6.5,-7.1,-7.7,-8.4
2017-09-08,0.2,0.9,-0.6,-0.4,-0.3,-2.6,-4.1,-5.5,-6.3,-6.9,-7.6
2017-09-11,-0.2,0.7,-0.9,0.2,0.2,-1.8,-3.5,-5.0,-5.9,-6.6,-7.3
2017-09-12,-0.9,0.1,-1.0,0.5,0.5,-1.3,-3.3,-4.8,-6.0,-6.7,-7.5
2017-09-13,0.6,1.0,-0.4,-0.9,-0.9,0.4,-1.9,-3.4,-4.8,-5.5,-6.3
2017-09-14,-0.5,0.7,-0.6,0.3,0.3,0.0,-1.7,-3.2,-4.7,-5.5,-6.2
2017-09-15,0.7,1.4,-0.3,-0.3,-0.3,0.3,-1.0,-2.5,-3.9,-4.8,-5.5
2017-09-18,-0.3,0.8,-0.7,0.4,0.4,-0.0,-0.9,-2.3,-3.7,-4.7,-5.5
2017-09-19,-0.4,0.3,-0.5,0.4,0.4,-0.4,-0.8,-2.2,-3.6,-4.7,-5.5

2017-09-06: rt AT_USER $bmy says opdivo multiple myeloma trials are on hold. no surprise given keytruda hold and subsequent fda news. |rt AT_USER following recent $mrk pembro news fda has placed partial clinical 
2017-09-07: rt AT_USER vantage snippet - keytruda¡¯s multiple myeloma fallout has roche in the firing line $mrk $bmy $azn $rhhby |rt AT_USER ipi/nivo beats sunitinib in 1l #kidneycancer by os. $bmy reports on pha
2017-09-08: bristol-myers squibb company $bmy svp joseph c. caldarella sells 9,340 shares |price moves vs expected moves $arry $abbv $mdt $agn $vrx $azn $biib $pfe $teva $bmy $gild $celg¡­ |update: $bmy also rele
2017-09-09: great slide by bmo expected sequence of events for key io trials in 1l-nsclc in 2h17, and our thoughts on implicati¡­ |rt AT_USER #crispr #cas9 offers grt hope for #glaucoma #opthalmology #ai $msft $g
2017-09-10: rt AT_USER presentation of day $bmy lag3 |$bmy heated as it hits the gap, hoping it rests and lest ma's catch up here |$bmy opdivo (nivolumab) demonstrates superior recurrence-free survival versus yer
2017-09-11: this week's most significant #insider trades: september 4-8, 2017 $bby $bmy $dps $f $hal $ph $psec $tjx¡­ |rt AT_USER mon-wed: morgan stanley 150 healthcare webcasts $abbv $agn $alxn $amgn $biib $blue
2017-09-12: s&amp;p100 #stocks performance $gd $amgn $msft $nee $rtn $bmy $celg $cat $fdx $jnj $pcln $mdt $dis $agn $intc  more@ |bristol-myers squibb company $bmy given average rating of ¡°hold¡± by analysts |th
2017-09-13: rt AT_USER event ¨c the next showdown in first-line lung cancer  $rhhby $bmy $mrk $azn|rt AT_USER just announced: leading cancer researcher karen vousden will join $bmy board of directors in january |
2017-09-14: seeking an edge in a fiercely fought field, $bmy pays $halo $105m to access i-o delivery tech #pharma |#bristolmyerssquibb bms inks $105m deal to access halozyme drug delivery tech. read more:  $bmy|#
2017-09-15: $halo ceo helen torley's relationship w/ $bmy didn't begin this week: |rt AT_USER willful manipulation, laziness, incompetence? $bmy escudier esmo cm-214 data dustup. must read story via AT_USER htt¡­
2017-09-16: rt AT_USER i'm counting days till first mention of $bmy's decision to study cancer immunotherapy subcutaneously via $halo enhanze by¡­|$bmy has a great technical rating! check out it's strong technica
2017-09-17: #bristolmyerssquibb halozyme leaps on news of multimillion dollar deals with bristolmyers an... read more:  $bmy|#bristolmyerssquibb this small cap biotech soars on deal with bristol-myers squibb. rea
2017-09-18: $bmy $mrk #stocks |rt AT_USER $bmy gorgeous coiled setup, size buyers of nov 65 calls today. |$bmy "they" are thinking about it. |rt AT_USER $bmy gorgeous coiled setup, size buyers of nov 65 calls tod
2017-09-19: evening most tweeted big caps, check out gambiste top 10: $jpm $ko $nvs $bmy $wbk $sny $msft $unh $pep $hd |$bmy is in three inside up winning 66.67% in the past. |rt AT_USER i called $bmy $halo 21 mo
Answer:+Rise